The global ophthalmic drugs market is expected to grow at a CAGR of 4.8% in the first half of the forecast period. The market is estimated at $25bn in 2018, dominated by the retinal disorder drugs segment.
How this report will benefit you Read on to discover how you can exploit the future business opportunities emerging in this sector.
In this brand new 298-page report you will receive 138 tables and 125 figures– all unavailable elsewhere.
The 298-page report provides clear detailed insight into the global ophthalmic drugs market. Discover the key drivers and challenges affecting the market.
By ordering and reading our brand-new report today you stay better informed and ready to act.
Report Scope
• Global Ophthalmic Drugs market forecasts from 2019-2029
• This report also breaks down the revenue forecasts to 2029 for the global ophthalmic drugs market by the leading submarkets: • Retinal Disorder Drugs • Allergic, Inflammatory & Infective Drugs • Glaucoma Drugs • Dry Eye Drugs • Other Ophthalmic Drugs
• This report includes revenue forecasts to 2029 for the following ophthalmic drugs: • Eylea • Lucentis • Avastin • Visudyne • Jetrea • Pataday • Vigamox • Patanol • TobraDex • Cravit • AzaSite • Acular • Lumigan and Ganfort • Xalatan/Xalacom • Travatan/Travatan Z and DuoTrav • Alphagan/Alphagan P and Combigan • Azopt • Trusopt • Zioptan • Cosopt • Tapros/Taflotan • Restasis • Refresh • Hyalein • Diquas
• This report provides individual revenue forecasts to 2029 for these national markets: • The US • Japan • EU5: Germany, France, the UK, Spain, Italy • Russia • China • India • Brazil • Rest of the World
Each national market is further segmented by the leading submarket: Retinal Disorder Drugs, Allergic, Inflammatory & Infective Drugs, Glaucoma Drugs, Dry Eye Drugs, Other Ophthalmic Drugs
• Our study provides a SWOT analysis and discusses Porter’s Five Forces analysis that influence the global ophthalmic drugs market
• Our report provides discussion on the ophthalmic drugs that are currently in the development pipeline
• Our study discusses the selected leading companies that are the major players in the ophthalmic drugs industry: • Allergan (Actavis) • Bayer • Novartis • Pfizer • Regeneron • Roche • Santen • Senju • Valeant
• Key Questions Answered by this Analysis: • How is the market for ophthalmic drugs evolving? • What is driving and restraining the ophthalmic drugs market dynamics? • What are the market shares of the submarkets for glaucoma drugs, allergic, inflammatory and infective drugs, dry eye drugs and retinal disorder drugs from the overall ophthalmic Drugs Market in 2018? • How will each of the submarket segments within the ophthalmic drugs market grow over the forecast period and how much revenue will these submarkets account for in 2029? • How will the market shares for each of the submarkets within the ophthalmic drugs market develop from 2018 to 2029? • Which submarkets will be the main driver of growth in the overall market from 2018 to 2029? • How will political, economic, and regulatory factors influence the regional markets and submarkets? • Will the leading regional markets for ophthalmic drugs broadly follow pre-existing trends, or will individual regions outperform the rest of the market? • How will the regional market shares in the ophthalmic drugs market change by 2029 and which geographical region will lead the market in 2029? • What are the predictions for partnerships, consolidation for existing players and the potential prospects for new market entrants? • How will the industry sector evolve as cost and pricing pressures increase during the period between 2018 and 2029?
Visiongain’s study is intended for anyone requiring commercial analyses for the global ophthalmic drugs market. You find data, trends and predictions.
Visiongain is a trading partner with the US Federal Government CCR Ref number: KD4R6
Do you have any custom requirements we can help you with? Any need for specific country, geo region, market segment or specific company information? Contact us today, we can discuss your needs and see how we can help: sara.peerun@visiongain.com
1. Report Overview 1.1 Global Ophthalmic Drugs: Market Overview 1.2 Global Ophthalmic Drugs Market Segmentation 1.3 Why You Should Read This Report 1.4 How This Report Delivers 1.5 Key Questions Answered by This Analytical Report 1.6 Who Is This Report For? 1.7 Methodology 1.8 Frequently Asked Questions (FAQ) 1.9 Associated Reports 1.10 About Visiongain
2. An Introduction to Ophthalmic Drugs 2.1 The Pharmaceutical Industry: A Brief Introduction 2.1.1 Ophthalmic Treatments – An Industry Overview 2.2 The Human Eyes – Structurally Delicate and Functionally Intricate Organs 2.3 The Global Burden of Eye Disease 2.4 Ophthalmic Drugs: Market Segmentation 2.5 Glaucoma: A Major Cause of Vision Loss 2.5.1 A Classification of Glaucoma 2.5.1.1 Primary Open-Angle Glaucoma 2.5.1.2 Acute Angle-Closure Glaucoma 2.5.1.3 Congenital Glaucoma 2.5.1.4 Secondary Glaucoma 2.5.1.5 Normal-Tension Glaucoma 2.5.1.6 Ocular Hypertension 2.5.2 Risk Factors for Glaucoma 2.5.3 Diagnosis of Glaucoma 2.5.4 Drug Treatment of Glaucoma 2.5.5 Laser Treatment and Surgery for Glaucoma 2.6 Age-Related Macular Degeneration (AMD) 2.6.1 Dry (non-exudative) AMD 2.6.2 Wet (exudative) AMD 2.6.3 Risk Factors for AMD 2.6.4 Diagnosis of AMD 2.6.5 Treatment of AMD 2.7 Diabetic Retinopathy (DR) 2.7.1 Diagnosis of Diabetic Retinopathy 2.7.2 Risk factor of Diabetic Retinopathy 2.7.3 Treatment of Diabetic Retinopathy 2.8 Ocular Allergy and Allergic Conjunctivitis 2.8.1 Diagnosis of Ocular Allergy 2.8.2 Treatment of Ocular Allergy 2.9 Ocular Inflammatory Disease 2.9.1 Risk factors of Ocular Inflammatory Disease 2.9.2 Treatment of Ocular Inflammatory Disease 2.10 Eye Infections 2.10.1 Treatment of Eye Infections 2.11 Dry Eye Syndrome 2.11.1 Treatment of Dry Eye Syndrome 2.12 Phases of Clinical Trials 2.13 Ophthalmic Drugs: Market Definition in This Report
3. The Global Ophthalmic Drugs Market, 2019-2029 3.1 The Global Ophthalmic Drugs Market: Market Overview 3.2 Categorisation of the Global Ophthalmic Drugs Market 3.3 The Global Ophthalmic Drugs Market In 2018 3.4 The Global Ophthalmic Drugs Market: Market Forecast 2018-2029 3.5 Ophthalmic Drugs: Changing Market Shares by Sector 2019-2029
4. The Retinal Disorder Drugs Market: Market Analysis and Forecast 2019-2029 4.1 Leading Products in the Retinal Disorder Drugs Market, 2018 4.2 Retinal Disorders: Market Trends and Developments, 2018 4.2.1 The Rise of Eylea 4.2.2 The Debate Around Off-Label Avastin Use and The Role of Novartis And Roche 4.2.3 How Likely Is Avastin’s Expansion into Age-Related Macular Degeneration? 4.2.4 Jetrea: Underwhelming Sales Cause ThromboGenics to Switch Focus to Their Pipeline 4.2.5 Drug/Device Combination Products Entering the Market 4.2.6 Does Regenerative Medicine Have a Successful Future in Ophthalmics? 4.3 Retinal Disorder Drugs: Market Forecast 2019-2029 4.3.1 Retinal Disorder Drugs: Changing Market Shares by Leading Drugs 2019-2029 4.4 Leading Drugs for The Treatment of Retinal Disorders 4.5 Eylea (aflibercept) - Regeneron/ Bayer/ Santen 4.5.1 Recent Approvals for Eylea 4.5.2 Eylea: Superior Clinical Outcomes than Lucentis and Avastin? 4.5.3 Eylea: Sales Forecast 2019-2029 4.5.4 Possible Combination Therapies Involving Eylea 4.6 Lucentis (ranibizumab) – Roche/ Novartis 4.6.1 Lucentis: Sales Forecast 2019-2029 4.6.2 Less Frequent Dosing Approved in US for Lucentis 4.6.3 New Indications for Lucentis 4.6.4 Possible Combination Therapy Involving Lucentis 4.7 Avastin (bevacizumab) - Roche 4.7.1 Avastin: Sales Forecast 2019-2029 4.7.2 Compounding Pharmacies and Safety Risks 4.8 Visudyne (verteporfin) - Valeant/ Novartis 4.8.1 Visudyne: Sales Forecast 2019-2029 4.9 Jetrea (ocriplasmin) - ThromboGenics/ Novartis 4.9.1 Jetrea: Recent Sales Performance 4.9.2 Clinical Study Plans for Jetrea 4.9.3 Jetrea: Sales Forecast 2019-2029 4.9.4 Possible Acquisition Move on ThromboGenics 4.9.5 R&D Agreements with Eleven Biotherapeutics and Bicycle Therapeutics 4.10 Other Retinal Disorder Drugs 4.10.1 Iluvien (fluocinolone implant) - Alimera Sciences 4.10.2 Ozurdex (dexamethasone implant) - Allergan 4.10.3 Other Retinal Disorder Drugs: Sales Forecast 2018-2029
5. Allergic, Inflammatory & Infective Drugs Market: Market Analysis and Forecast 2019-2029 5.1 Leading Products in The Allergic, Inflammatory and Infective Drugs Market, 2018 5.2 Allergic, Inflammatory and Infective Drugs: Market Trends and Developments, 2018 5.2.1 The Growth Prospects for Allergic, Inflammatory and Infective Drugs 5.2.2 Topical NSAIDs Launched: Prolensa and Ilevro 5.3 Allergic, Inflammatory and Infective Drugs: Market Forecast 2019-2029 5.3.1 Allergic, Inflammatory and Infective Drugs: Changing Market Shares by Leading Drugs 2019-2029 5.4 Leading Drugs for The Treatment of Allergic, Inflammatory and Infective Ophthalmic Conditions 5.5 Patanol And Pataday (olopatadine) - Alcon (Novartis) 5.5.1 Pataday: Sales Forecast 2018-2029 5.5.2 Impending Generic Competition for Patanol And Pataday 5.5.3 Approval of Pazeo Solution 5.5.4 Patanol: Sales Forecast 2019-2029 5.6 Vigamox (moxifloxacin) – Alcon (Novartis) 5.6.1 Intensifying Competition and Generics Drug Challenge to Vigamox 5.6.2 Moxeza: A Next-Generation Form of Vigamox 5.6.3 Vigamox: Sales Forecast 2019-2029 5.7 TobraDex (tobramycin/dexamethasone) – Alcon (Novartis) 5.7.1 The Development and Commercialisation of TobraDex ST 5.7.2 TobraDex: Sales Forecast 2019-2029 5.8 Cravit (levofloxacin) - Santen 5.8.1 Cravit: Sales Forecast 2019-2029 5.9 Acular (ketorolac) – Allergan (Actavis) 5.9.1 Acular: Sales Forecast 2019-2029 5.10 AzaSite (azithromycin) - Akorn 5.10.1 AzaSite: Sales Forecast 2019-2029 5.11 Other Allergic, Inflammatory, and Infective Drugs: Sales Forecast 2019-2029
6. Glaucoma Drugs Market: Market Analysis and Forecast 2019-2029 6.1 Glaucoma Drugs: Market Overview 6.1.1 Leading Products in The Glaucoma Drugs Market, 2018 6.2 Glaucoma Drugs: Market Trends and Developments, 2018 6.2.1 Patent Expiration: A Major Restraint for Glaucoma Drugs 6.2.2 Preservative-Free Formulation Trends 6.2.3 Innovation in Treatments for Glaucoma 6.3 Simbrinza: First Beta-Blocker-Free Combination 6.4 Glaucoma Drugs: Market Forecast 2019-2029 6.4.1 Glaucoma Drugs: Changing Market Shares by Leading Drugs 2019-2029 6.5 Leading Drugs for The Treatment of Glaucoma 6.6 Lumigan And Ganfort (bimatoprost) – Allergan (Actavis) 6.6.1 Lumigan And Ganfort: Sales Forecast 2018-2029 6.7 Xalatan And Xalacom (latanoprost) - Pfizer 6.7.1 Xalatan/Xalacom: Sales Forecast 2019-2029 6.8 Travatan/Travatan Z and DuoTrav (travoprost) - Novartis 6.8.1 Travatan/Travatan Z and DuoTrav: Sales Forecast 2019-2029 6.9 Alphagan/Alphagan P and Combigan (brimonidine) - Allergan 6.9.1 Alphagan/Alphagan P and Combigan: Sales Forecast 2019-2029 6.10 Trusopt And Cosopt/Cosopt PF (dorzolamide) – Merck/ Santen 6.10.1 Divestment Agreement with Santen And Akorn 6.10.2 Trusopt: Sales Forecast 2019-2029 6.10.3 Cosopt And Cosopt PF: Sales Forecast 2019-2029 6.11 Azopt (brinzolamide) - Novartis 6.11.1 Azopt: Sales Forecast 2019-2029 6.12 Tapros (tafluprost) – Santen 6.12.1 Tapros: Sales Forecast 2019-2029 6.13 Zioptan (tafluprost) - Akorn 6.13.1 Zioptan: Sales Forecast 2019-2029 6.14 Other Glaucoma Drugs: Sales Forecast 2019-2029
7. Dry Eye Drugs Market: Market Analysis and Forecast 2019-2029 7.1 Dry Eye Drugs: Market Overview 7.1.1 Leading Products in The Dry Eye Drugs Market, 2018 7.2 Dry Eye Drugs: Market Trends and Developments, 2018 7.2.1 Restasis: Patent Elongations and Generic Challenges Creating Uncertainty 7.2.2 Intensifying Research Focused on Dry Eye 7.2.3 Improving Diagnostic Tools 7.3 Dry Eye Drugs: Market Forecast 2019-2029 7.3.1 Dry Eye Drugs: Changing Market Shares by Leading Drugs 2019-2029 7.4 Leading Drugs for The Treatment of Dry Eye 7.5 Restasis (ciclosporin) – Allergan (Actavis) 7.5.1 Restasis – Generic launch in 2016? 7.5.2 Restasis: Sales Forecast 2019-2029 7.6 Refresh Brand Products – Allergan (Actavis) 7.6.1 Refresh Brand Products: Sales Forecast 2019-2029 7.7 Hyalein (hyaluronic acid) - Santen 7.7.1 Hyalein: Sales Forecast 2019-2029 7.8 Diquas (diaquafosol) - Santen 7.8.1 Diquas: Sales Forecast 2019-2029 7.9 Other Dry Eye Drugs: Sales Forecast 2019-2029 7.10 Other Ophthalmic Drugs 7.10.1 Hetlioz (tasimelteon) - Vanda Pharmaceuticals 7.10.2 Hetlioz: Sales Forecast 2019-2029
8. Leading National Markets for Ophthalmic Drugs, 2019-2029 8.1 The Ophthalmic Drugs Market by Region 8.1.1 The Global Distribution of Ophthalmic Drugs In 2018 8.2 Leading National Markets: Forecast 2019-2029 8.2.1 Changing Market Shares by Region, 2019-2029 8.3 Regional Ophthalmic Drugs Markets: Analysis and Forecasts, 2019-2029 8.4 United States: The Largest Ophthalmic Drugs Market 8.4.1 How Will the Rise of a Biosimilars Market Impact on US Ophthalmic Drugs? 8.4.2 US Ophthalmic Drugs Market: Market Forecast 2018-2029 8.5 EU5 8.5.1 EU5 Ophthalmic Drugs Market: Market Forecast 2018-2029 8.5.1.1 EU5 Markets: Changing Market Shares by Country, 2019-2029 8.5.2 Germany 8.5.2.1 German Ophthalmic Drugs Market: Market Forecast 2019-2029 8.5.3 France 8.5.3.1 French Ophthalmic Drugs Market: Market Forecast 2019-2029 8.5.4 UK 8.5.4.1 UK Ophthalmic Drugs Market: Market Forecast 2019-2029 8.5.4.2 Brexit – Increased Uncertainty May Affect the UK Ophthalmic Drug Market 8.5.5 Italy 8.5.5.1 Italian Ophthalmic Drugs Market: Market Forecast 2019-2029 8.5.6 Spain 8.5.6.1 Spanish Ophthalmic Drugs Market: Market Forecast 2019-2029 8.6 Japan 8.6.1 The Cost of Treatment in Japan 8.6.2 Japanese Pharmaceutical Industry Regulatory Reform 8.6.3 Japanese Ophthalmic Drugs Market Forecast 2019-2029 8.7 China 8.7.1 Expansion of Healthcare Coverage and Reimbursement in China 8.7.2 Price Controls and The Anhui Model 8.7.3 Chinese Ophthalmic Drugs Market: Market Forecast 2019-2029 8.8 Brazil 8.8.1 How Will Brazil’s Growing Healthcare Influence Ophthalmic Drugs 8.8.2 Brazilian Ophthalmic Drugs Market: Market Forecast 2019-2029 8.9 Russia 8.9.1 How Will Russia’s Economic Status Affect Its Pharma Industry? 8.9.2 Russian Ophthalmic Drugs Market: Market Forecast 2019-2029 8.10 India 8.10.1 The Impact of The Drug Prices Control Order on Indian Pharma 8.10.2 India’s Expansion of Healthcare Provision 8.10.3 Indian Ophthalmic Drugs Market: Market Forecast 2019-2029 8.11 Rest of the World 8.11.1 Rest of the World Ophthalmic Drugs Market: Market Forecast 2019-2029
9. Leading Companies in the Ophthalmic Drugs Market, 2019-2029 9.1 Ophthalmic Drugs – A Changing Market Landscape 9.2 Leading Companies in The Ophthalmic Drugs Market, 2018 9.2.1 Ophthalmic Drugs Market: Leading Companies Forecast 2019-2029 9.2.2 Ophthalmic Drugs: Changing Market Shares by Leading Companies 2019-2029 9.3 Novartis (Alcon) 9.3.1 Novartis: Ophthalmic Drugs Portfolio 9.3.2 Novartis: Sales Forecast 2019-2029 9.3.3 Novartis: Ophthalmic Drugs Development Pipeline 9.3.4 Novartis: Recent Developments 9.3.4.1 Novartis Restructures Following Strategic Review 9.3.4.2 Novartis Licenses Ophthotech’s Fovista 9.4 Regeneron 9.4.1 Regeneron: Ophthalmic Drugs Portfolio 9.4.2 Regeneron: Recent Developments 9.4.2.1 Expanding Indications for Eylea 9.4.2.2 Eylea/Zaltrap And the Davis-Smyth Patent Agreements 9.4.3 Regeneron: Sales Forecast 2019-2029 9.4.4 Regeneron: Ophthalmic Drugs Development Pipeline 9.5 Allergan (Actavis) 9.5.1 Allergan: Ophthalmic Drugs Portfolio 9.5.2 Allergan: Recent Developments 9.5.2.1 Ozurdex (Dexamethasone Intravitreal Implant): The First Drug Therapy for Diabetic Macular Oedema 9.5.2.2 How Real Is the Threat of Generic Restasis? 9.5.2.3 Valeant’s Attempted Takeover Squashed by Actavis Bid 9.5.3 New acqusitions for healthcare development 9.5.4 Allergan: Sales Forecast 2019-2029 9.5.5 Allergan: Ophthalmic Drugs Development Pipeline 9.6 Roche 9.6.1 Roche: Ophthalmic Drugs Portfolio 9.6.1.1 Lucentis: US Sales Forecast 2019-2029 9.6.2 Roche: Sales Forecast 2019-2029 9.6.3 Roche: Ophthalmic Drugs Development Pipeline 9.7 Valeant 9.7.1 Valeant: Ophthalmic Drugs Portfolio 9.7.2 Valeant: Recent Developments 9.7.2.1 Valeant’s Acquisition of Bausch and Lomb Still Driving Its Ophthalmic Portfolio 9.7.3 Valeant: Sales Forecast 2019-2029 9.7.4 Valeant: Ophthalmic Drugs Development Pipeline 9.7.5 Valeant: Difficult End to 2015 as well as 2016 Leads to Uncertainty About Company Future 9.8 Santen 9.8.1 Santen: Ophthalmic Drugs Portfolio 9.8.2 Santen: Recent Developments 9.8.2.1 Santen Acquires Novagali Pharma 9.8.2.2 Santen Acquires Merck’s Ophthalmic Drugs Portfolio 9.8.3 Santen: Sales Forecast 2019-2029 9.8.4 Santen: Ophthalmic Drugs Development Pipeline 9.9 Bayer 9.9.1 Bayer: Ophthalmic Drugs Portfolio 9.9.2 Bayer: Sales Forecast 2019-2029 9.10 Pfizer 9.10.1 Pfizer: Ophthalmic Drugs Portfolio 9.10.1.1 Xalatan/Xalacom – Pfizer’s Leading Ophthalmic Products 9.10.1.2 Macugen - Valeant/Pfizer 9.10.2 Pfizer: Recent Developments 9.10.2.1 Pfizer Attempts to Acquire AstraZeneca 9.10.2.2 Pfizer Attempts Merger with Allergan 9.10.3 Pfizer: Sales Forecast 2019-2029 9.10.4 Pfizer: Ophthalmic Drugs Development Pipeline 9.11 Senju 9.11.1 Senju: Ophthalmic Drugs Portfolio 9.11.2 Senju: Sales Forecast 2019-2029 9.11.3 Senju: Ophthalmic Drugs Development Pipeline 9.11.3.1 Y 39983 (SNJ 1656) 9.11.3.2 Difluprednate (SJE-2079)
10. Ophthalmic Drugs: Research and Development Pipeline, 2019-2029 10.1 The Ophthalmic Drugs Pipeline: Intensive Development Efforts in Retinal Disorders 10.2 Drugs for Retinal Disorders: Development Pipeline 10.2.1 Will Bevasiranib (RXi Pharmaceuticals) Resume Development? 10.3 Retinal Disorders: Filed or Recently Launched 10.3.1 CompaqSipp (conbercept) – Chengdu Kanghong Pharmaceutical 10.3.2 Lipidil (fenofibrate) - Abbott 10.3.3 Iluvien (fluocinolone) – Alimera Sciences 10.4 Drugs in Phase 3 Development for Retinal Disorders 10.4.1 AGN150998 And MP0260 (Anti-VEGFDARPins) - Allergan 10.4.2 Fovista and Zimura – Ophthotech Corporation 10.4.3 Lampalizumab (anti-FactorD Fab) - Roche 10.4.4 MC-1101 (hydralazine) – Macu CLEAR 10.4.5 Squalamine (anti-angiogenic drug) - OHRPharmaceutical 10.4.6 Tandospirone (serotonin 1A agonist) – Alcon (Novartis) 10.4.7 UF-021 (unoprostone) - R-TechUeno 10.5 Drugs in Phase 2 Development for Retinal Disorders 10.5.1 AKB-9778 (Tie2 activator) - AerpioTherapeutics 10.5.2 Luminate (ALG-1001; Integrin peptide therapy) - Allegro/Senju 10.5.3 AGN208397 (beclomethasone) - Allergan 10.5.4 CPC 551 - ColbyPharmaceutical 10.5.5 ESBA1008 (anti-VEGF mAb) – Alcon (Novartis) 10.5.6 iCo-007 (antisense inhibitor of C-raf kinase mRNA) - iCo Therapeutics 10.5.7 LFG316 (anti-C5 mAb) - Novartis 10.5.8 Intravitreal brimonidine implant - Allergan 10.5.9 Optina (danazol) – Ampio Pharmaceuticals 10.5.10 PF-655 (synthetic siRNA) - Quark/Pfizer 10.5.11 Premiplex (SHP-607) - Shire 10.5.12 Renexus (ciliary neurotrophic factor) - Neurotech 10.5.13 Zybrestat (fosbretabulin) - Oxigene/SymphonyVIDA 10.6 DrugsInPhase 1 and Pre-clinical Developmentfor RetinalDisorders 10.6.1 BDM-E - BioDiem 10.6.2 NADPHOxidaseInhibitors – AlimeraSciences 10.6.3 PAN-90806 (topical VEGF inhibitor) - PanOptica 10.6.4 PlasmaKallikreinInhibitors (KVD001) - KalVista 10.6.5 QLT091001 (synthetic retinoid) – QLT 10.7 Drugs in Phase 3 Development for Allergic, Inflammatory and Infective Ophthalmic Conditions 10.7.1 EGP-437 (dexamethasone) – EyeGate Pharmaceuticals 10.7.2 IBI-10090 and IBI-20089 - IconBioscience 10.7.3 KPI-121 (loteprednol etabonate) - Kala 10.8 Drugs in Phase 2 Development for Allergic, Inflammatory and Infective Ophthalmic Conditions 10.8.1 CF101 (adenosine A3 receptor agonist) - Can-Fite BioPharma and OphthaliX 10.8.2 FST-100 (povidone-iodine/dexamethasone) - Shire 10.8.3 NVC-422 (auriclosene) - NovaBay 10.8.4 Sarilumab - Regeneron 10.9 Drugs in Phase 1 And Pre-clinical Development for Allergic, Inflammatory and Infective Ophthalmic Conditions 10.9.1 Finafloxacin – MerLion Pharmaceuticals/Novartis 10.10 Drugs for Glaucoma: Development Pipeline, 2016 10.11 Drugs in Phase 2&3 Development for Glaucoma 10.11.1 Latanoprostene Bunod (VESNEO; BOL 303259-X) - Valeant 10.11.2 AMA0076 (ROCK inhibitor) - Amakem 10.11.3 Rhopressa (AR-13324; ROCK and NET inhibitor) AndRoclatan (PG324; ROCK inhibitor) – Aerie Pharmaceuticals 10.12 Drugs in Phase 1 And Pre-clinical Development for Glaucoma 10.13 Drugs in Phase 3 Development for Dry Eye 10.13.1 EBI-005 (IL-1R antagonist) – Eleven Biotherapeutics 10.13.2 Lifitegrast (integrin antagonist) - Shire 10.13.3 Tavilermide (formerly MIM-D3tyrosine kinase receptor antagonist) - Allergan 10.13.4 SI-614 (modified hyaluronate) - Seikagaku 10.14 Drugs in Phase 2 Development for Dry Eye 10.14.1 ESBA105 (TNF-alpha antibody) - Alcon (Novartis) 10.14.2 Kineret (anakinra: IL-1 receptor antagonist) - Amgen/Sobi 10.15 Other Drugs in the Development Pipeline for Ophthalmic Conditions 10.15.1 Brimonidine For Eye Whitening - Valeant 10.15.2 GS-101 (aganirsen) - GeneSignal 10.15.3 Omidria (phenylephrine/ketorolac) – Omeros
11. Qualitative Analysis of the Ophthalmic Drugs Market, 2019-2029 11.1 Market Factors Influencing Ophthalmic Drugs 11.2 SWOT Analysis of the Global Ophthalmic Drugs Market, 2019-2029 11.3 Strengths 11.3.1 A Healthy R&D Pipeline 11.3.2 Advances in Drug Delivery Technologies 11.3.3 Support for Reimbursement and Payment Approvals 11.3.4 Gene Therapy and RNAi Technology 11.3.5 New Ophthalmic Therapeutic Applications for Drugs 11.3.6 Development of Neuroprotective Anti-Glaucoma Medications 11.3.7 Biomarkers as Tools for Better Diagnosis and Treatment 11.4 Weaknesses 11.4.1 Low Levels of Patient Adherence to Treatment 11.4.2 High Treatment Burden on Patients and Healthcare Providers 11.4.3 Under-Diagnosis and Under-Treatment 11.5 Opportunities 11.5.1 Sustained-Release Ocular Implants 11.5.2 The Impact of a Rapidly Ageing Global Population 11.5.3 Increasing Prevalence of Diabetes and Ocular Disease 11.5.4 Glaucoma and Retinal Disorders Set for Most-Marked Increases in Prevalence 11.5.5 Unmet Clinical Need in Many Disease Areas 11.5.6 Economic Growth in Emerging Market Provide Opportunity for Expansion 11.6 Threats 11.6.1 Intensifying Price Regulation in The Market 11.6.2 Generic Competition – Likely to Cause Erosion of Sales for Market Leading Brands 11.6.3 Rising Cost Of R&D 11.6.4 Biosimilars – A Bigger Threat than Generics? 11.7 Porter’s Five Force Analysis of The Global Ophthalmic Drugs Market, 2019-2029 11.7.1 Threat of New Entrants 11.7.2 Rivalry Among Competitors 11.7.3 Power of Suppliers 11.7.4 Threat of Substitutes 11.7.5 Power of Buyers
12. Conclusions 12.1 Overview of Current Market Conditions and Market Forecast, 2019-2029 12.2 Leading Sectors in Ophthalmic Drugs In 2018 12.3 Leading Regions in the Ophthalmic Drugs Market In 2018 12.4 Leading Companies in The Ophthalmic Drugs Market, 2018 12.5 What Does the Future Hold for Ophthalmic Drugs?
Appendices Glossary Associated Reports Visiongain Report Sales Order Form
List of Tables Table 2.1 ICD 10 Classification of Visual Impairment, 2010 Table 2.2 Main Classes of the Glaucoma Drugs Table 2.3 Drug Treatments for Age-Related Macular Degeneration, 2017 Table 2.4 Drug Treatments for Ocular Allergy Table 2.5 Drug Treatments for Ocular Inflammatory Disease, 2017 Table 2.6 Drug Treatments for Eye Infections, 2017 Table 2.7 Clinical Trial Phases Table 3.1 The Global Ophthalmic Drugs Market: Revenue ($m) and Market Share (%) by Segment, 2018 Table 3.2 The Global Ophthalmic Drugs Market: Market Forecast ($m, AGR%, CAGR%) by Sector, 2019-2029 Table 3.3 The Global Ophthalmic Drugs Market Forecast: CAGR (%) by Sector, 2018-2023, 2023-2029, 2018-2029 Table 3.4 The Global Ophthalmic Drugs Market: Revenue ($m) and Market Share (%) by Sector, 2018, 2023, 2029 Table 4.1 Top Drugs in The Retinal Disorder Drugs Market: Revenue ($m) and Market Shares (%), 2018 Table 4.2 Retinal Disorder Drugs Market: Market Forecast ($m, AGR%, CAGR%) by Leading Drugs, 2019-2029 Table 4.3 The Global Retinal Disorder Drugs Market: Market Share (%) by Leading Drugs, 2018, 2023, 2029 Table 4.4 Eylea: Regeneron/ Bayer/ Santen Sales Forecast ($m), AGR (%) and CAGR (%), 2019-2029 Table 4.5 Lucentis: Novartis/ Roche Sales Forecast ($m, AGR%, CAGR%), 2019-2029 Table 4.6 Avastin: Ophthalmic Sales Forecast ($m, AGR%, CAGR%), 2019-2029 Table 4.7 Visudyne: Sales Forecast ($m, AGR%, CAGR%), 2019-2029 Table 4.8 Jetrea: ThromboGenics/ Novartis Sales Forecast ($m, AGR%, CAGR%), 2019-2029 Table 4.9 Other Retinal Disorder Drugs: Sales Forecast ($m, AGR%, CAGR%), 2019-2029 Table 5.1 Leading Drugs in The Allergic, Inflammatory and Infective Drugs Market: Revenue ($m) and Market Shares (%), 2018 Table 5.2 Allergic, Inflammatory and Infective Drugs Market: Market Forecast ($m, AGR%, CAGR%) by Leading Drugs, 2019-2029 Table 5.3 The Global Allergic, Inflammatory and Infective Drugs Market: Market Share (%) by Leading Drugs, 2018, 2023, 2029 Table 5.4 Pataday: Novartis/Kyowa Hakko Kirin Sales Forecast ($m, AGR%, CAGR%), 2019-2029 Table 5.5 Patanol: Novartis/Kyowa Hakko Kirin Sales Forecast ($m, AGR%, CAGR%), 2019-2029 Table 5.6 Vigamox: Novartis Sales Forecast ($m, AGR%, CAGR%), 2019-2029 Table 5.7 TobraDex: Sales Forecast ($m, AGR%, CAGR%), 2019-2029 Table 5.8 Cravit: Sales Forecast ($m, AGR%, CAGR%), 2019-2029 Table 5.9 Acular: Sales Forecast ($m, AGR%, CAGR%), 2018-2029 Table 5.10 AzaSite: Akorn Sales Forecast ($m, AGR%, CAGR%), 2019-2029 Table 5.11 Other Allergic, Inflammatory, And Infective Drugs: Sales Forecast ($m, AGR%, CAGR%), 2019-2029 Table 6.1 Leading Glaucoma Drugs: Revenues ($m) and Market Shares (%), 2018 Table 6.2 Glaucoma Drugs Market: Market Forecast ($m, AGR%, CAGR%) by Leading Drugs, 2019-2029 Table 6.3 The Global Glaucoma Drugs Market: Market Share (%) by Leading Drugs, 2018, 2023, 2029 Table 6.4 Lumigan and Ganfort: Sales Forecast ($m, AGR%, CAGR%), 2018-2029 Table 6.5 Xalatan/Xalacom: Sales Forecast ($m, AGR%, CAGR%), 2019-2029 Table 6.6 Travatan/Travatan Z and DuoTrav: Sales Forecast ($m, AGR%, CAGR%), 2019-2029 Table 6.7 Alphagan/Alphagan P and Combigan: Sales Forecast ($m, AGR%, CAGR%), 2019-2029 Table 6.8 Trusopt: Merck/Santen Sales Forecast ($m, AGR%, CAGR%), 2019-2029 Table 6.9 Cosopt/Cosopt PF: Akorn/Merck/Santen Sales Forecast ($m, AGR%, CAGR%), 2019-2029 Table 6.10 Azopt: Novartis Sales Forecast ($m, AGR%, CAGR%), 2019-2029 Table 6.11 Tapros: Santen Sales Forecast ($m, AGR%, CAGR%), 2018-2029 Table 6.12 Zioptan: Akorn Sales Forecast ($m, AGR%, CAGR%), 2019-2029 Table 6.13 Other Glaucoma Drugs: Sales Forecast ($m, AGR%, CAGR%), 2019-2029 Table 7.1 Leading Dry Eye Drugs: Revenues ($m) and Market Shares (%), 2018 Table 7.2 Dry Eye Drugs Market: Market Forecast ($m, AGR%, CAGR%) by Leading Drugs, 2019-2029 Table 7.3 The Global Dry Eye Drugs Market: Market Share (%) by Leading Drugs, 2018, 2023, 2029 Table 7.4 Restasis: Allergan (Actavis) Sales Forecast ($m, AGR%, CAGR%), 2019-2029 Table 7.5 Refresh Brand: Allergan (Actavis) Sales Forecast ($m, AGR%, CAGR%), 2019-2029 Table 7.6 Hyalein: Santen Sales Forecast ($m, AGR%, CAGR%), 2019-2029 Table 7.7 Diquas: Santen Sales Forecast ($m, AGR%, CAGR%), 2019-2029 Table 7.8 Other Dry Eye Drugs: Sales Forecast ($m, AGR%), 2019-2029 Table 7.9 Hetlioz: Vanda Pharma Sales Forecast ($m, AGR%, CAGR%), 2019-2029 Table 8.1 The Global Ophthalmic Drugs Market: Market Size ($m) and Market Share (%) by Region, 2018 Table 8.2 Global Ophthalmic Drugs Market: Market Forecast ($m, AGR%, CAGR%) by Region, 2019-2029 Table 8.3 The Global Ophthalmic Drugs Market Forecast: CAGR (%) by Region, 2018-2023, 2023-2029, and 2018-20289 Table 8.4 The Global Ophthalmic Drugs Market Forecast: Market Share (%) by Region, 2018, 2023, and 2029 Table 8.5 The US Ophthalmic Drugs Market Forecast: Revenue ($m), Rank, Market Share (%) and CAGR (%), 2018-2029 Table 8.6 US Ophthalmic Drugs Market: Market Forecast ($m, AGR%, CAGR%), 2019-2029 Table 8.7 The US Ophthalmic Drugs Market Forecast by Sector, 2019-2029 Table 8.8 EU5 Ophthalmic Drugs Market Forecast: Revenue ($m), Market Share (%) and CAGR (%), 2018-2029 Table 8.9 EU5 Ophthalmic Drugs Market: Revenue ($m), and Market Share (%) by Country, 2018 Table 8.10 EU5 Ophthalmic Drugs Market: Market Forecast ($m, AGR%, CAGR%), 2019-2029 Table 8.11 EU5 Ophthalmic Drugs Market Forecast by Sector, 2019-2029 Table 8.12 EU5 Ophthalmic Drugs Market: Market Share (%) by Country, 2018, 2023, 2029 Table 8.13 The German Ophthalmic Drugs Market Forecast: Revenue ($m), Rank, Market Share (%) and CAGR (%), 2018-2029 Table 8.14 The German Ophthalmic Drugs Market: Market Forecast ($m, AGR%, CAGR%), 2019-2029 Table 8.15 The Germany Ophthalmic Drugs Market Forecast by Sector, 2019-2029 Table 8.16 The French Ophthalmic Drugs Market Forecast: Revenue ($m), Rank, Market Share (%) and CAGR (%), 2018-2029 Table 8.17 The French Ophthalmic Drugs Market: Market Forecast ($m, AGR%, CAGR%), 2019-2029 Table 8.18 France Ophthalmic Drugs Market Forecast by Sector, 2019-2029 Table 8.19 The UK Ophthalmic Drugs Market Forecast: Revenue ($m), Rank, Market Share (%) and CAGR (%), 2018-2029 Table 8.20 The UK Ophthalmic Drugs Market: Market Forecast ($m, AGR%, CAGR%), 2019-2029 Table 8.21 UK Ophthalmic Drugs Market Forecast by Sector, 2019-2029 Table 8.22 The Italian Ophthalmic Drugs Market Forecast: Revenue ($m), Rank, Market Share (%) and CAGR (%), 2018-2029 Table 8.23 The Italian Ophthalmic Drugs Market: Market Forecast ($m, AGR%, CAGR%), 2019-2029 Table 8.24 Italy Ophthalmic Drugs Market Forecast by Sector, 2019-2029 Table 8.25 The Spanish Ophthalmic Drugs Market Forecast: Revenue ($m), Rank, Market Share (%) and CAGR (%), 2018-2029 Table 8.26 The Spanish Ophthalmic Drugs Market: Market Forecast ($m, AGR%, CAGR%), 2019-2029 Table 8.27 Spain Ophthalmic Drugs Market Forecast by Sector, 2019-2029 Table 8.28 The Japanese Ophthalmic Drugs Market Forecast: Revenue ($m), Rank, Market Share (%) and CAGR (%), 2018-2029 Table 8.29 The Japanese Ophthalmic Drugs Market: Market Forecast ($m, AGR%, CAGR%), 2019-2029 Table 8.30 Japan Ophthalmic Drugs Market Forecast by Sector, 2019-2029 Table 8.31 The Chinese Ophthalmic Drugs Market Forecast: Revenue ($m), Rank, Market Share (%) and CAGR (%), 2018-2029 Table 8.32 The Chinese Ophthalmic Drugs Market: Market Forecast ($m, AGR%, CAGR%), 2019-2029 Table 8.33 China Ophthalmic Drugs Market Forecast by Sector, 2019-2029 Table 8.34 The Brazilian Ophthalmic Drugs Market Forecast: Revenue ($m), Rank, Market Share (%) and CAGR (%), 2019-2029 Table 8.35 The Brazilian Ophthalmic Drugs Market: Market Forecast ($m, AGR%, CAGR%), 2019-2029 Table 8.36 Brazil Ophthalmic Drugs Market Forecast by Sector, 2019-2029 Table 8.37 The Russian Ophthalmic Drugs Market Forecast: Revenue ($m), Rank, Market Share (%) and CAGR (%), 2017-2028 Table 8.38 The Russian Ophthalmic Drugs Market: Market Forecast ($m, AGR%, CAGR%), 2019-2029 Table 8.39 Russia Ophthalmic Drugs Market Forecast by Sector, 2019-2029 Table 8.40 The Indian Ophthalmic Drugs Market Forecast: Revenue ($m), Rank, Market Share (%) and CAGR (%), 2018-2029 Table 8.41 The Indian Ophthalmic Drugs Market: Market Forecast ($m, AGR%, CAGR%), 2019-2029 Table 8.42 India Ophthalmic Drugs Market Forecast by Sector, 2019-2029 Table 8.43 The Rest of the World Ophthalmic Drugs Market Forecast: Revenue ($m), Rank, Market Share (%) and CAGR (%), 2018-2029 Table 8.44 The Rest of the World Ophthalmic Drugs Market: Market Forecast ($m, AGR%, CAGR%), 2019-2029 Table 8.45 Row Ophthalmic Drugs Market Forecast by Sector, 2019-2029 Table 9.1 Leading Ophthalmic Drug Companies: Revenues ($m) and Market Shares (%), 2018 Table 9.2 Ophthalmic Drugs Market: Market Forecast ($m, AGR%, CAGR%) by Leading Companies, 2019-2029 Table 9.3 The Global Ophthalmic Drugs Market: Market Share (%) by Leading Companies, 2018, 2023, 2029 Table 9.4 Novartis: Company Overview, 2018 Table 9.5 Novartis: Ophthalmic Drugs Revenue Forecast ($m, AGR%, CAGR%), 2019-2029 Table 9.6 Regeneron: Company Overview, 2018 Table 9.7 Regeneron: Ophthalmic Drugs Revenue Forecast ($m, AGR%, CAGR%), 2019-2029 Table 9.8 Allergan: Company Overview, 2018 Table 9.9 Allergan: Ophthalmic Drugs Revenue Forecast ($m, AGR%, CAGR%), 2019-2029 Table 9.10 Roche: Company Overview, 2018 Table 9.11 Lucentis (Roche): US Revenue Forecast ($m, AGR%, CAGR%), 2019-2029 Table 9.12 Roche: Ophthalmic Drugs Revenue Forecast ($m, AGR%, CAGR%), 2019-2029 Table 9.13 Valeant: Company Overview, 2018 Table 9.14 Valeant: Ophthalmic Drugs Revenue Forecast ($m, AGR%, CAGR%), 2019-2029 Table 9.15 Santen: Company Overview, 2016 Table 9.16 Santen: Ophthalmic Drugs Revenue Forecast ($m, AGR%, CAGR%), 2019-2029 Table 9.17 Bayer: Company Overview, 2018 Table 9.18 Bayer: Ophthalmic Drugs Revenue Forecast ($m, AGR%, CAGR%), 2019-2029 Table 9.19 Pfizer: Company Overview, 2016 Table 9.20 Pfizer: Ophthalmic Drugs Revenue Forecast ($m, AGR%, CAGR%), 2019-2029 Table 9.21 Senju: Company Overview, 2018 Table 9.22 Senju: Ophthalmic Drugs Revenue Forecast ($m, AGR%, CAGR%), 2019-2029 Table 9.23 Other Companies: Ophthalmic Drugs Revenue Forecast ($m, AGR%, CAGR%), 2019-2029 Table 10.1 Retinal Disorders Drugs Pipeline: Phase 3 Drugs Table 10.2 Retinal Disorders Drugs Pipeline: Phase 2 Drugs Table 10.3 Retinal Disorders Drugs Pipeline: Phase 1 and Pre-clinical Drugs Table 10.4 Allergic, Inflammatory and Infective Drugs Pipeline: Phase 3 Drugs Table 10.5 Allergic, Inflammatory and Infective Drugs Pipeline: Phase 2 Drugs Table 10.6 Allergic, Inflammatory and Infective Drugs Pipeline: Phase 1 and Pre-clinical Drugs Table 10.7 Glaucoma Drugs Pipeline: Phase 2&3 Drugs Table 10.8 GlaucomaDrugsPipeline: Phase 1 and Pre-clinical Drugs Table 10.9 DryEyeDrugsPipeline: Phase 3 Drugs Table 10.10 DryEyeDrugsPipeline: Phase 2 Drugs Table 10.11 OtherPipelineProducts for OphthalmicConditions Table 11.1 SWOT Analysis of the Global Ophthalmic Drugs Market, 2019-2029 Table 11.2 World 65+ Population Forecast: Size (m), AGR (%), CAGR (%), 2017-2028 Table 11.3 Global Prevalence Forecast for Ophthalmic Diseases Table 12.1 Global Ophthalmic Drugs: Market Forecast ($m, CAGR%), 2018, 2023 and 2029 Table 12.2 The Global Ophthalmic Drugs Market: Market Forecast ($m) by Region, 2018, 2023, 2029 Table 12.3 Top ten ophthalmic drug companies in 2018
List of Figures Figure 1.1 Global Ophthalmic Drugs Market: Market Sectors, 2018 Figure 2.1 Structure of The Human Eye Figure 2.2 Estimated Global Prevalence of Visual Impairment (millions of people), 2014 Figure 2.3 Global Causes of Visual Impairment (% of cases), 2012 Figure 2.4 Classification of Glaucoma, 2016 Figure 3.1 The Global Ophthalmic Drugs Market: Revenue ($m) by Sector, 2018 Figure 3.2 The Global Ophthalmic Drugs Market: Market Forecast ($m, AGR%), 2019-2029 Figure 3.3 The Global Ophthalmic Drugs Market Forecast: CAGR (%) by Sector, 2018-2023 Figure 3.4 The Global Ophthalmic Drugs Market Forecast: CAGR (%) by Sector, 2023-2029 Figure 3.5 The Global Ophthalmic Drugs Market Forecast: CAGR (%) by Sector, 2018-2029 Figure 3.6 The Global Ophthalmic Drugs Market: Market Share (%) by Sector, 2018 Figure 3.7 The Global Ophthalmic Drugs Market: Market Share (%) by Sector, 2023 Figure 3.8 The Global Ophthalmic Drugs Market: Market Share (%) by Sector, 2029 Figure 4.1 Top Drugs in The Retinal Disorder Drugs Market: Revenue ($m), 2018 Figure 4.2 Retinal Disorder Drugs Market: Market Forecast ($m, AGR%), 2019-2029 Figure 4.3 Retinal Disorder Drugs Market: Revenue Forecast ($m) by Leading Drugs, 2019-2029 Figure 4.4 The Global Retinal Disorder Drugs Market: Market Share (%) by Leading Drugs, 2018 Figure 4.5 The Global Retinal Disorder Drugs Market: Market Share (%) by Leading Drugs, 2023 Figure 4.6 The Global Retinal Disorder Drugs Market: Market Share (%) by Leading Drugs, 2029 Figure 4.7 Eylea: Regeneron/ Bayer/ Santen Sales Forecast ($m, AGR%), 2019-2029 Figure 4.8 Lucentis: Novartis/ Roche Sales Forecast ($m, AGR%), 2019-2029 Figure 4.9 Avastin: Ophthalmic Sales Forecast ($m, AGR%), 2019-2029 Figure 4.10 Visudyne: Sales Forecast ($m, AGR%), 2018-2029 Figure 4.11 Jetrea: ThromboGenics/ Novartis Sales Forecast ($m, AGR%), 2018-2029 Figure 4.12 Other Retinal Disorder Drugs: Sales Forecast ($m, AGR%), 2019-2029 Figure 5.1 Leading Drugs in The Allergic, Inflammatory and Infective Drugs Market: Revenue ($m), 2018 Figure 5.2 Allergic, Inflammatory and Infective Drugs Market: Market Forecast ($m, AGR%), 2019-2029 Figure 5.3 Allergic, Inflammatory and Infective Drugs Market: Market Forecast ($m, AGR%) by Leading Drugs, 2019-2029 Figure 5.4 The Global Allergic, Inflammatory and Infective Drugs Market: Market Share (%) by Leading Drugs, 2018 Figure 5.5 The Global Allergic, Inflammatory and Infective Drugs Market: Market Share (%) by Leading Drugs, 2023 Figure 5.6 The Global Allergic, Inflammatory and Infective Drugs Market: Market Share (%) by Leading Drugs, 2028 Figure 5.7 Pataday: Novartis/Kyowa Hakko Kirin Sales Forecast ($m, AGR%), 2018-2029 Figure 5.8 Patanol: Novartis/Kyowa Hakko Kirin Sales Forecast ($m, AGR%), 2019-2029 Figure 5.9 Vigamox: Novartis Sales Forecast ($m, AGR%), 2019-2029 Figure 5.10 TobraDex: Sales Forecast ($m, AGR%), 2019-2029 Figure 5.11 Cravit: Sales Forecast ($m, AGR%), 2019-2029 Figure 5.12 Acular: Sales Forecast ($m, AGR%), 2018-2029 Figure 5.13 AzaSite: Akorn Sales Forecast ($m, AGR%), 2018-2028 Figure 5.14 Other Allergic, Inflammatory, And Infective Drugs: Sales Forecast ($m, AGR%), 2019-2029 Figure 6.1 Leading Glaucoma Drugs: Revenue ($m), 2018 Figure 6.2 Glaucoma Drugs Market: Market Forecast ($m, AGR%), 2019-2029 Figure 6.3 Glaucoma Drugs Market: Market Forecast ($m, AGR%) by Leading Drugs, 2019-2029 Figure 6.4 The Global Glaucoma Drugs Market: Market Share (%) by Leading Drugs, 2018 Figure 6.5 The Global Glaucoma Drugs Market: Market Share (%) by Leading Drugs, 2023 Figure 6.6 The Global Glaucoma Drugs Market: Market Share (%) by Leading Drugs, 2029 Figure 6.7 Lumigan and Ganfort: Sales Forecast ($m, AGR%), 2018-2029 Figure 6.8 Xalatan/Xalacom: Sales Forecast ($m, AGR%), 2019-2029 Figure 6.9 Travatan/Travatan Z and DuoTrav: Sales Forecast ($m, AGR%), 2019-2029 Figure 6.10 Alphagan/Alphagan P and Combigan: Sales Forecast ($m, AGR%), 2019-2029 Figure 6.11 Trusopt: Merck/Santen Sales Forecast ($m, AGR%), 2019-2029 Figure 6.12 Cosopt/Cosopt PF: Akorn/Merck/Santen Sales Forecast ($m, AGR%), 2019-2029 Figure 6.13 Azopt: Novartis Sales Forecast ($m, AGR%), 2019-2029 Figure 6.14 Tapros: Santen Sales Forecast ($m, AGR%), 2018-2029 Figure 6.15 Zioptan: Akorn Sales Forecast ($m, AGR%), 2019-2029 Figure 6.16 Other Glaucoma Drugs: Sales Forecast ($m, AGR%), 2019-2029 Figure 7.1 Leading Dry Eye Drugs: Revenue ($m), 2018 Figure 7.2 Dry Eye Drugs Market: Market Forecast ($m, AGR%), 2019-2029 Figure 7.3 Dry Eye Drugs Market: Market Forecast ($m, AGR%) by Leading Drugs, 2019-2029 Figure 7.4 The Global Dry Eye Drugs Market: Market Share (%) by Leading Drugs, 2018 Figure 7.5 The Global Dry Eye Drugs Market: Market Share (%) by Leading Drugs, 2023 Figure 7.6 The Global Dry Eye Drugs Market: Market Share (%) by Leading Drugs, 2029 Figure 7.7 Restasis: Allergan (Actavis) Sales Forecast ($m, AGR%), 2019-2029 Figure 7.8 Refresh Brand: Allergan (Actavis) Sales Forecast ($m, AGR%), 2019-2029 Figure 7.9 Hyalein: Santen Sales Forecast ($m, AGR%), 2018-2029 Figure 7.10 Diquas: Santen Sales Forecast ($m, AGR%), 2018-2029 Figure 7.11 Other Dry Eye Drugs: Sales Forecast ($m, AGR%, CAGR%), 2019-2029 Figure 7.12 Hetlioz: Vanda Pharma Sales Forecast ($m, AGR%), 2019-2029 Figure 8.1 The Global Ophthalmic Drugs Market: Market Size ($m) by Region, 2018 Figure 8.2 US, EU5, China and Japan Ophthalmic Drugs Market: Market Forecast ($m), 2019-2029 Figure 8.3 Brazil, Russia and India Ophthalmic Drugs Market: Market Forecast ($m), 2018-2029 Figure 8.4 The Global Ophthalmic Drugs Market Forecast: CAGR (%) by Region, 2018-2023 Figure 8.5 The Global Ophthalmic Drugs Market Forecast: CAGR (%) by Region, 2023-2029 Figure 8.6 The Global Ophthalmic Drugs Market Forecast: Market Share (%) by Region, 2018 Figure 8.7 The Global Ophthalmic Drugs Market Forecast: Market Share (%) by Region, 2023 Figure 8.8 The Global Ophthalmic Drugs Market Forecast: Market Share (%) by Region, 2029 Figure 8.9 US Ophthalmic Drugs Market: Market Forecast ($m, AGR%), 2019-2029 Figure 8.10 US Ophthalmic Drugs Market: Sub- Market Forecast, 2019-2029 Figure 8.11 EU5 Ophthalmic Drugs Market: Revenue ($m) by Country, 2018 Figure 8.12 Germany, France, UK, Italy, and Spain Ophthalmic Drugs Market: Market Forecast ($m), 2019-2029 Figure 8.13 EU5 Ophthalmic Drugs Market: Sub- Market Forecast, 2019-2029 Figure 8.14 EU5 Ophthalmic Drugs Market: Market Share (%) by Country, 2018 Figure 8.15 EU5 Ophthalmic Drugs Market: Market Share (%) by Country, 2023 Figure 8.16 EU5 Ophthalmic Drugs Market: Market Share (%) by Country, 2029 Figure 8.17 The German Ophthalmic Drugs Market: Market Forecast ($m, AGR%), 2019-2029 Figure 8.18 Germany Ophthalmic Drugs Market: Sub- Market Forecast, 2019-2029 Figure 8.19 The French Ophthalmic Drugs Market: Market Forecast ($m, AGR%), 2019-2029 Figure 8.20 France Ophthalmic Drugs Market: Sub- Market Forecast, 2019-2029 Figure 8.21 The UK Ophthalmic Drugs Market: Market Forecast ($m, AGR%), 2019-2029 Figure 8.22 UK Ophthalmic Drugs Market: Sub- Market Forecast, 2019-2029 Figure 8.23 The Italian Ophthalmic Drugs Market: Market Forecast ($m, AGR%), 2019-2029 Figure 8.24 Italy Ophthalmic Drugs Market: Sub- Market Forecast, 2019-2029 Figure 8.25 The Spanish Ophthalmic Drugs Market: Market Forecast ($m, AGR%), 2019-2029 Figure 8.26 Spain Ophthalmic Drugs Market: Sub- Market Forecast, 2019-2029 Figure 8.27 The Japanese Ophthalmic Drugs Market: Market Forecast ($m, AGR%), 2019-2029 Figure 8.28 Japan Ophthalmic Drugs Market: Sub- Market Forecast, 2019-2029 Figure 8.29 The Chinese Ophthalmic Drugs Market: Market Forecast ($m, AGR%), 2019-2029 Figure 8.30 China Ophthalmic Drugs Market: Sub- Market Forecast, 2019-2029 Figure 8.31 The Brazilian Ophthalmic Drugs Market: Market Forecast ($m, AGR%), 2019-2029 Figure 8.32 Brazil Ophthalmic Drugs Market: Sub- Market Forecast, 2019-2029 Figure 8.33 The Russian Ophthalmic Drugs Market: Market Forecast ($m, AGR%), 2019-2029 Figure 8.34 Russia Ophthalmic Drugs Market: Sub- Market Forecast, 2019-2029 Figure 8.35 The Indian Ophthalmic Drugs Market: Market Forecast ($m, AGR%), 2019-2029 Figure 8.36 India Ophthalmic Drugs Market: Sub- Market Forecast, 2019-2029 Figure 8.37 The Rest of the World Ophthalmic Drugs Market: Market Forecast ($m, AGR%), 2019-2029 Figure 8.38 ROW Ophthalmic Drugs Market: Sub- Market Forecast, 2019-2029 Figure 9.1 Leading Ophthalmic Drug Companies: Revenue ($m), 2018 Figure 9.2 Ophthalmic Drugs Market: Market Forecast ($m) by Leading Companies, 2019-2029 Figure 9.3 The Global Ophthalmic Drugs Market: Market Share (%) by Leading Companies, 2018 Figure 9.4 The Global Ophthalmic Drugs Market: Market Share (%) by Leading Companies, 2023 Figure 9.5 The Global Ophthalmic Drugs Market: Market Share (%) by Leading Companies, 2029 Figure 9.6 Novartis: Ophthalmic Drugs Revenue Forecast ($m, AGR%), 2019-2029 Figure 9.7 Regeneron: Ophthalmic Drugs Revenue Forecast ($m, AGR%), 2019-2029 Figure 9.8 Allergan: Ophthalmic Drugs Revenue Forecast ($m, AGR%), 201-2029 Figure 9.9 Lucentis (Roche): US Revenue Forecast ($m, AGR%), 2018-2029 Figure 9.10 Roche: Ophthalmic Drugs Revenue Forecast ($m, AGR%), 2019-2029 Figure 9.11 Valeant: Ophthalmic Drugs Revenue Forecast ($m, AGR%), 2019-2029 Figure 9.12 Santen: Ophthalmic Drugs Revenue Forecast ($m, AGR%), 2019-2029 Figure 9.13 Bayer: Ophthalmic Drugs Revenue Forecast ($m, AGR%), 2019-2029 Figure 9.14 Pfizer: Ophthalmic Drugs Revenue Forecast ($m, AGR%), 2019-2029 Figure 9.15 Senju: Ophthalmic Drugs Revenue Forecast ($m, AGR%), 2019-2029 Figure 11.1 World 65+ Population Forecast: Size (m), AGR (%), 2017-2028 Figure 11.2 Global Prevalence of Diabetes and Diabetic Retinopathy, 2010 and 2030 Figure 11.3 Porter’s Five Force Analysis of the Ophthalmic Drugs Market, 2017 Figure 12.1 Global Ophthalmic Drugs: Market Forecast ($m), 2018 - 2029 Figure 12.2 The Global Ophthalmic Drugs Market: Market Forecast ($m) by Region, 2018-2029
List of Organizations Mentioned in the Report American Academy of Ophthalmology (AAO) American Society of Retina Specialists (ASRS) CDSCO (India) European Union European Commission Health Canada (Canada) Institute of Experimental Medicine Italian Competition Authority (ICA) Italian National Health Service Japanese Ministry of Health, Labour and Welfare (MHLW) MCC (South Africa) MHLW (Japan) MHRA (UK) PAHO SFDA (China) TGA (Australia) University of Modena US National Eye Institute (NEI) World Health Organization (WHO) WIPO WTO
Download sample pages
Complete the form below to download your free sample pages for Global Ophthalmic Drugs Market Forecast 2019-2029
Visiongain’s reports are based on comprehensive primary and secondary research. Those studies provide global market forecasts (sales by drug and class, with sub-markets and leading nations covered) and analyses of market drivers and restraints (including SWOT analysis) and current pipeline developments. To find out more about our reports methodology, please email sara.peerun@visiongain.com
“Thank you for this Gene Therapy R&D Market report and for how easy the process was. Your colleague was very helpful and the report is just right for my purpose. This is the 2nd good report from Visiongain and a good price.” Dr Luz Chapa Azuella, Mexico
The global AI-based Clinical Trial Solution Providers market was valued at US$1,232.0 million in 2022 and is projected to grow at a CAGR of 23.3% during the forecast period 2023-2033.
Visiongain Pharma
Visiongain Pharma
Visiongain Pharma
